Beijing Tide Pharmaceutical Becomes Biggest Shareholder Of Japanese LTT Bio-Pharma
This article was originally published in PharmAsia News
Executive Summary
According to a recent disclosure filed by LTT Bio-Pharma, a Japanese biotech startup focusing on drug delivery system discovery, Beijing Tide Pharmaceutical acquired 2,320 company shares previously owned by now-bankrupt Asklepios and became the largest shareholder with 25,320 shares. The shares account for 19.2 percent of LTT Bio-Pharma's outstanding shares. (Click here for more - Japanese languageYou may also be interested in...
Lannett Reports Insulin Glargine Trial Success
Lannett’s Phase I trial for biosimilar insulin glargine has met “all primary endpoints,” the company has announced. The rival to Sanofi’s Lantus is being developed by Lannett with partner HEC through a deal for which financial details have just been revealed.
BREAKING: Sanofi Forms Standalone Consumer Healthcare Unit: Prelude To Spin-Off?
Sanofi Consumer Healthcare is to operate as a standalone unit in a move which is being viewed as a prelude to a potential spin-off. High profile prescription-to-OTC switches are a priority for the revamped business.
Data Integrity Remains Challenging For API Manufacturers
Data integrity issues were raised in many warning letters to active pharmaceutical ingredient manufacturers over the past four years.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports